NO911020L - Fremgangsmaate og preparat for koiontoforese. - Google Patents

Fremgangsmaate og preparat for koiontoforese. Download PDF

Info

Publication number: NO911020L
Authority: NO; Norway
Prior art keywords: active ingredient; vasoactivator; animal; skin; delivery
Prior art date: 1990-03-15

Application number

NO91911020A

Other languages

English (en)

Norwegian (no)

Other versions

NO911020D0 (no

Inventor

Jr Burton H Sage

James E Riviere

Original Assignee

Becton Dickinson Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-15

Filing date

1991-03-14

Publication date

1991-09-16

1991-03-14 Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co

1991-03-14 Publication of NO911020D0 publication Critical patent/NO911020D0/no

1991-09-16 Publication of NO911020L publication Critical patent/NO911020L/no

Links

238000000034 method Methods 0.000 title claims description 38
238000002360 preparation method Methods 0.000 title claims description 6
239000004480 active ingredient Substances 0.000 claims description 141
241001465754 Metazoa Species 0.000 claims description 61
230000017531 blood circulation Effects 0.000 claims description 49
229940124549 vasodilator Drugs 0.000 claims description 49
239000003071 vasodilator agent Substances 0.000 claims description 49
239000000203 mixture Substances 0.000 claims description 45
238000009472 formulation Methods 0.000 claims description 43
210000005166 vasculature Anatomy 0.000 claims description 39
239000005526 vasoconstrictor agent Substances 0.000 claims description 32
230000005684 electric field Effects 0.000 claims description 19
230000001965 increasing effect Effects 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 13
150000002500 ions Chemical class 0.000 claims description 12
239000003085 diluting agent Substances 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
230000037317 transdermal delivery Effects 0.000 claims description 9
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 8
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 8
229960002312 tolazoline Drugs 0.000 claims description 7
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 6
-1 mecolyl Chemical compound 0.000 claims description 6
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims description 4
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 4
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 claims description 4
229960000729 cyclandelate Drugs 0.000 claims description 4
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
229960002768 dipyridamole Drugs 0.000 claims description 4
229960001340 histamine Drugs 0.000 claims description 4
229960004819 isoxsuprine Drugs 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
150000002823 nitrates Chemical class 0.000 claims description 4
229960001789 papaverine Drugs 0.000 claims description 4
229960001999 phentolamine Drugs 0.000 claims description 4
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 4
230000008859 change Effects 0.000 claims description 3
230000004913 activation Effects 0.000 claims 1
210000003491 skin Anatomy 0.000 description 64
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 22
229960004194 lidocaine Drugs 0.000 description 22
150000001875 compounds Chemical class 0.000 description 17
210000000434 stratum corneum Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 8
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
230000004907 flux Effects 0.000 description 6
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
229960002748 norepinephrine Drugs 0.000 description 6
230000002500 effect on skin Effects 0.000 description 5
230000004888 barrier function Effects 0.000 description 4
238000010586 diagram Methods 0.000 description 4
230000035515 penetration Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
229930182837 (R)-adrenaline Natural products 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
229960005139 epinephrine Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000013271 transdermal drug delivery Methods 0.000 description 3
230000032258 transport Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000037365 barrier function of the epidermis Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Radiology & Medical Imaging (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO91911020A 1990-03-15 1991-03-14 Fremgangsmaate og preparat for koiontoforese. NO911020L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49406290A	1990-03-15	1990-03-15

Publications (2)

Publication Number	Publication Date
NO911020D0 NO911020D0 (no)	1991-03-14
NO911020L true NO911020L (no)	1991-09-16

Family

ID=23962871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO91911020A NO911020L (no)	1990-03-15	1991-03-14	Fremgangsmaate og preparat for koiontoforese.

Country Status (10)

Country	Link
US (2)	US5334138A (fr)
EP (1)	EP0448300A3 (fr)
JP (1)	JPH07103046B2 (fr)
KR (3)	KR910016316A (fr)
AU (1)	AU7270091A (fr)
CA (1)	CA2038097C (fr)
FI (1)	FI911267A7 (fr)
IE (1)	IE910714A1 (fr)
NO (1)	NO911020L (fr)
ZA (2)	ZA911875B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE64891B1 (en) *	1990-03-15	1995-09-20	Becton Dickinson Co	Composition for increased skin concentration of active agents by iontophoresis
US6004309A (en)	1990-03-30	1999-12-21	Alza Corporation	Method and apparatus for controlled environment electrotransport
US5125894A (en) *	1990-03-30	1992-06-30	Alza Corporation	Method and apparatus for controlled environment electrotransport
US6060000A (en) *	1992-11-12	2000-05-09	Implemed, Inc.	Iontophoretic material containing carbon and metal granules
US6287484B1 (en)	1992-11-12	2001-09-11	Robert Hausslein	Iontophoretic material
US5750141A (en) *	1993-04-08	1998-05-12	The University Of Queensland	Administration of vaso-active agent and therapeutic agent
AU681390B2 (en) *	1993-04-08	1997-08-28	University Of Queensland, The	Administration of vaso-active agent and therapeutic agent
US6377847B1 (en) *	1993-09-30	2002-04-23	Vyteris, Inc.	Iontophoretic drug delivery device and reservoir and method of making same
US20050159698A1 (en) *	1993-09-30	2005-07-21	Vyteris, Inc.	Iontophoretic drug delivery device and reservoir and method of making same
DK0752898T3 (da) *	1994-03-30	1999-02-15	Alza Corp	Mindskning af hudirritation ved elektrotransport-tilførsel
US5990179A (en) *	1995-04-28	1999-11-23	Alza Corporation	Composition and method of enhancing electrotransport agent delivery
US5620416A (en) *	1995-06-07	1997-04-15	North Carolina State University	Methods of using topical agents with systemically administered active agents
US5788666A (en) *	1995-06-15	1998-08-04	Empi, Inc.	Iontophoresis electrode
US5840056A (en) *	1995-06-15	1998-11-24	Empi, Inc.	Iontophoresis electrode
US5833647A (en) *	1995-10-10	1998-11-10	The Penn State Research Foundation	Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery
ATE271839T1 (de) *	1996-04-16	2004-08-15	Pathagon Inc	Iontophoretische struktur
US5759564A (en) *	1996-04-16	1998-06-02	Implemed, Inc.	Iontophoretic material
WO1997048443A1 (fr) *	1996-06-19	1997-12-24	Becton Dickinson And Company	Administration iontophoretique d'inhibiteurs de l'adhesion cellulaire
US7033598B2 (en) *	1996-11-19	2006-04-25	Intrabrain International N.V.	Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6246904B1 (en)	1996-12-17	2001-06-12	Alza Corporation	Electrotransport drug delivery reservoirs containing inert fillers
US6650934B2 (en)	1996-12-17	2003-11-18	Alza Corp	Polymeric foam reservoirs for an electrotransport delivery device
US6119036A (en)	1997-03-26	2000-09-12	The Board Of Regents Of The University Of Oklahoma	Iontophoretic transdermal delivery device
US5954675A (en) *	1997-07-07	1999-09-21	Dellagatta; Enrico Michael	Method of ultrasonic therapy
CA2308489A1 (fr)	1997-10-09	1999-04-22	Emory University	Procede et dispositif d'administration transdermique du lithium
US6295469B1 (en)	1997-11-14	2001-09-25	Alza Corporation	Formulation for electrically assisted delivery of lidocaine and epinephrine
US6319901B1 (en) *	1998-10-15	2001-11-20	Ichor Medical Systems, Inc.	Methods for prolonging cell membrane permeability
US6730691B1 (en)	2000-02-10	2004-05-04	Miles A. Galin	Uses of alpha adrenergic blocking agents
US6560483B1 (en) *	2000-10-18	2003-05-06	Minnesota High-Tech Resources, Llc	Iontophoretic delivery patch
US6553255B1 (en)	2000-10-27	2003-04-22	Aciont Inc.	Use of background electrolytes to minimize flux variability during iontophoresis
US20030065285A1 (en) *	2001-07-23	2003-04-03	Higuchi William I.	Method and apparatus for increasing flux during reverse iontophoresis
US20030092774A1 (en) *	2001-10-17	2003-05-15	Parkinson Thomas M.	Methods for treating neoplastic, angiogenic, vascular, fibroblastic, and/or immunosuppressive iregularities of the eye and/or joint via administration of combretastatin based medicaments, and iontophoretic devices for delivering combretastatin based medicaments
US7099713B2 (en)	2002-06-28	2006-08-29	Battelle Memorial Institute	Skin conduction and transport systems
US7666914B2 (en) *	2004-06-03	2010-02-23	Richlin David M	Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20060013769A1 (en) *	2004-07-16	2006-01-19	Stephen Carter	Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US20060013866A1 (en) *	2004-07-16	2006-01-19	Carter Stephen G	Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060062836A1 (en) *	2004-09-21	2006-03-23	Carter Stephen G	Methods of device-assisted drug delivery
US20060089590A1 (en) *	2004-10-27	2006-04-27	John Higuchi	Methods and devices for sustained in-vivo release of an active agent
WO2006055729A1 (fr) *	2004-11-16	2006-05-26	Transcutaneous Technologies Inc.	Dispositif iontophoretique et procede pour adminstrer des agents ameliorant la reponse immunitaire et des compositions
JP2006296511A (ja) *	2005-04-15	2006-11-02	Transcutaneous Technologies Inc	外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ
WO2007041158A1 (fr) *	2005-09-30	2007-04-12	Vyteris, Inc.	Dispositif d'administration de medicament par iontophorese engendrant une profondeur et une duree acceptables d'anesthesie dermique
WO2007041323A1 (fr) *	2005-09-30	2007-04-12	Tti Ellebeau, Inc.	Apport ionophoretique d'agents actifs encapsules dans des vesicules
US20070083185A1 (en) *	2005-09-30	2007-04-12	Darrick Carter	Iontophoretic device and method of delivery of active agents to biological interface
JP2009509676A (ja) *	2005-09-30	2009-03-12	Ｔｔｉ・エルビュー株式会社	ナノ粒子と接合された活性物質のイオントフォレーシス送達
EP1931417A2 (fr) *	2005-09-30	2008-06-18	Transcutaneous Technologies Inc.	Systemes d'administration transdermique de medicament, dispositifs, et methodes faisant intervenir de nouveaux excipients pharmaceutiques
WO2007041475A2 (fr) *	2005-09-30	2007-04-12	Vyteris, Inc.	Formulation d'administration de medicament par ionophorese assurant une sensation acceptable et une anesthesie dermique
WO2007041476A2 (fr) *	2005-09-30	2007-04-12	Vyteris, Inc.	Indications pour le transport local d'agents anesthesiques par des dispositifs d' electrotransport
US20070135754A1 (en) *	2005-09-30	2007-06-14	Hidero Akiyama	Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
EP2269689A1 (fr) *	2005-09-30	2011-01-05	Vyteris Inc.	Administration par impulsions d'hormone de libération des gonadotropines à partir d'un patch d'électrotransport intégré préchargé
US20090221985A1 (en) *	2005-10-19	2009-09-03	Shmuel Bukshpan	System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof
JP2009522011A (ja)	2005-12-30	2009-06-11	Ｔｔｉ・エルビュー株式会社	活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法
US20080193514A1 (en) *	2006-11-02	2008-08-14	Transcu Ltd.	Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
JPWO2008087803A1 (ja) *	2007-01-16	2010-05-06	国立大学法人北海道大学	抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
MX2009012273A (es) *	2007-05-18	2010-04-09	Tti Ellebeau Inc	Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
JP2010187707A (ja) *	2007-06-12	2010-09-02	Hokkaido Univ	インスリンを封入したイオントフォレーシス用リポソーム製剤
CA2724949A1 (fr)	2007-06-27	2008-12-31	The General Hospital Corporation	Procede et appareil d'inhibition optique de traitement photodynamique
US20100069877A1 (en) *	2008-09-10	2010-03-18	Smith Gregory A	Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3991755A (en) *	1973-07-27	1976-11-16	Medicon, Inc.	Iontophoresis apparatus for applying local anesthetics
US4406658A (en) *	1981-03-06	1983-09-27	Medtronic, Inc.	Iontophoretic device with reversible polarity
US4820263A (en) *	1981-03-06	1989-04-11	Medtronic, Inc.	Apparatus and method for iontophoretic drug delivery
JPS5810066A (ja) *	1981-07-10	1983-01-20	株式会社アドバンス	イオントフオレ−ゼ用プラスタ−構造体
US4702732A (en) *	1984-12-24	1987-10-27	Trustees Of Boston University	Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4752285B1 (en) *	1986-03-19	1995-08-22	Univ Utah Res Found	Methods and apparatus for iontophoresis application of medicaments
IE60941B1 (en) *	1986-07-10	1994-09-07	Elan Transdermal Ltd	Transdermal drug delivery device
CA1317522C (fr) *	1987-03-20	1993-05-11	Dan Sibalis	Systeme de delivrance transdermique des medicaments
AU615188B2 (en) *	1987-05-28	1991-09-26	Drug Delivery Systems Inc.	Pulsating transdermal drug delivery system
FR2616333A1 (fr) *	1987-06-12	1988-12-16	Cird	Procede d'ionophorese pour administrer une substance dissoute ou partiellement dissoute, par voie percutanee ou perungueale et dispositif correspondant
US4845233A (en) *	1987-09-11	1989-07-04	Iprx, Inc.	Imidazolin-2-ones
US5068226A (en) *	1987-12-07	1991-11-26	Cyclex, Inc.	Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5057072A (en) *	1988-10-28	1991-10-15	Medtronic, Inc.	Iontophoresis electrode
US5088977A (en) *	1988-12-21	1992-02-18	Drug Delivery Systems Inc.	Electrical transdermal drug applicator with counteractor and method of drug delivery
US4950229A (en) *	1989-09-25	1990-08-21	Becton, Dickinson And Company	Apparatus for an electrode used for iontophoresis
US5023085A (en) *	1989-11-29	1991-06-11	Pfizer Inc.	Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5047007A (en) *	1989-12-22	1991-09-10	Medtronic, Inc.	Method and apparatus for pulsed iontophoretic drug delivery
US5084008A (en) *	1989-12-22	1992-01-28	Medtronic, Inc.	Iontophoresis electrode
US5084006A (en) *	1990-03-30	1992-01-28	Alza Corporation	Iontopheretic delivery device
US5087620A (en) *	1990-05-17	1992-02-11	Bristol-Myers Squibb Co.	Controlled dermal penetration enhancement using imidazoles

1991
- 1991-02-08 US US07/653,204 patent/US5334138A/en not_active Expired - Fee Related
- 1991-02-08 US US07/653,202 patent/US5302172A/en not_active Expired - Lifetime
- 1991-03-04 IE IE071491A patent/IE910714A1/en unknown
- 1991-03-07 AU AU72700/91A patent/AU7270091A/en not_active Abandoned
- 1991-03-12 CA CA002038097A patent/CA2038097C/fr not_active Expired - Fee Related
- 1991-03-14 NO NO91911020A patent/NO911020L/no unknown
- 1991-03-14 ZA ZA911875A patent/ZA911875B/xx unknown
- 1991-03-14 FI FI911267A patent/FI911267A7/fi unknown
- 1991-03-14 ZA ZA911876A patent/ZA911876B/xx unknown
- 1991-03-15 KR KR1019910004165A patent/KR910016316A/ko not_active Ceased
- 1991-03-15 JP JP3051725A patent/JPH07103046B2/ja not_active Expired - Lifetime
- 1991-03-15 EP EP19910302221 patent/EP0448300A3/en not_active Withdrawn
- 1991-03-15 KR KR1019910004167A patent/KR930005320B1/ko not_active Expired - Fee Related
- 1991-03-15 KR KR1019910004166A patent/KR930005319B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JPH06183999A (ja)	1994-07-05
IE910714A1 (en)	1991-09-25
US5302172A (en)	1994-04-12
NO911020D0 (no)	1991-03-14
KR930005320B1 (ko)	1993-06-17
FI911267A0 (fi)	1991-03-14
AU7270091A (en)	1991-09-19
US5334138A (en)	1994-08-02
KR910016317A (ko)	1991-11-05
JPH07103046B2 (ja)	1995-11-08
CA2038097C (fr)	1997-01-07
ZA911876B (en)	1992-03-25
KR910016316A (ko)	1991-11-05
KR930005319B1 (ko)	1993-06-17
KR910016318A (ko)	1991-11-05
EP0448300A3 (en)	1991-12-27
ZA911875B (en)	1992-03-25
FI911267A7 (fi)	1991-09-16
CA2038097A1 (fr)	1991-09-16
EP0448300A2 (fr)	1991-09-25

Publication	Publication Date	Title
EP0448300A2 (fr)	1991-09-25	Méthode et composition de coiontophorèse
KR100856693B1 (ko)	2008-09-04	항미생물제 양립가능성 저장소 조성물을 포함하는 경피전기수송 전달 장치
DK175043B1 (da)	2004-05-10	Indretning til iontophoretisk medikamenttilförsel
Kari	1986	Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin
JP4049389B2 (ja)	2008-02-20	電気的移送式作用剤投与のための組成物、デバイス及び方法
Jue-Chen et al.	1988	Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin
JP4090072B2 (ja)	2008-05-28	経皮電気的移送式作用剤投与を促進するための組成物と方法
EP1080731A2 (fr)	2001-03-07	Composition et structure d'un dispositif pour ionophorèse
AU2002303239A1 (en)	2003-04-10	Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
JPH05339170A (ja)	1993-12-21	皮膚を横切る薬物の移送法およびその方法において有用な組成物および物品
US5861439A (en)	1999-01-19	Method for enhanced electrotransport agent delivery
CA2132348C (fr)	2000-02-01	Dispositif iontophoretique a commandes et methode d'utilisation
EP0448299B1 (fr)	1994-06-01	Composition d'iontophorèse pour augmenter la concentration d'agents actifs dans la peau
DE69105322T2 (de)	1995-05-18	Iontophoreseverfahren und -zusammensetzung.
Bhat et al.	0	Pharmacology & Pharmacotherapeutics